News
NUMIF
0.051
0.00%
0.000
Weekly Report: what happened at NUMIF last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at NUMIF last week (0415-0419)?
Weekly Report · 04/22 11:39
CEDAR CLINICAL RESEARCH SELECTED AS CLINICAL RESEARCH SITE FOR CYBIN'S PHASE 3 STUDY OF CYB003
Reuters · 04/17 11:00
NUMINUS WELLNESS INC: PHASE 3 TRIAL FOR CYB003 IS PLANNED TO COMMENCE ENROLLMENT MID-2024 AND FOCUS ON ITS SAFETY AND EFFICACY
Reuters · 04/17 11:00
Stocks in play: Numinus Wellness Inc.
Barchart · 04/17 08:51
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Psychedelics healthcare company Numinus Wellness reported its interim financial results for the three and six months ended February 29, 2024. The company is developing a model to help people heal through psychedelic therapies. Revenues declined 15.4% in Q2 2024, with 15 clinical trials managed in the quarter.
Benzinga · 04/15 20:13
NUMINUS WELLNESS PROVIDES CORPORATE UPDATE
Reuters · 04/15 11:41
NUMINUS WELLNESS INC - CANADIAN REORGANIZATION IS A STRATEGIC SHIFT FOR NUMINUS AND WILL ALLOW IT TO FOCUS ON ITS CLINICAL OPERATIONS IN UNITED STATES
Reuters · 04/15 11:41
NUMINUS WELLNESS-GOT INTO NON-BINDING LETTER OF INTENT WITH A CANADIAN CENTRE FOR PSYCHEDELIC HEALING RELATED TO A PART OF CANADIAN REORGANIZATION
Reuters · 04/15 11:41
Weekly Report: what happened at NUMIF last week (0408-0412)?
Weekly Report · 04/15 11:30
Numinus Wellness reports Q2 results
Numinus Wellness reports Q2 results. Revenue of C$5M (-6.5% Y/Y). Enrolment in Numinus training programs doubled to over 1,400 in Q2 2024. The company ended the quarter with a cash position of $6.6 million.
Seeking Alpha · 04/15 05:02
Notable earnings after Monday's close
Major earnings expected after the bell on Monday include: Remark Holdings, Mitek Systems, Vuzix Corporation and Mark Holdings. Notable earnings after Monday's close include: MiteK, MARK, VUZI, NUMIF, and REMark Holdings. For the full earnings calendar, click here.
Seeking Alpha · 04/14 21:35
Numinus Wellness Q2 Earnings Preview
Seeking Alpha · 04/14 21:35
NUMINUS WELLNESS INC. ANNOUNCES SECOND QUARTER FISCAL 2024 RESULTS
Reuters · 04/12 23:49
NUMINUS WELLNESS Q2 GROSS MARGIN 33%
Reuters · 04/12 23:49
Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results
Numinus Wellness Inc. Announced its financial results for the three months ended February 29, 2024. The company is a mental health care company advancing traditional and innovative behavioral health treatments. Numinus has a focus on safe, evidence-based psychedelic-assisted therapies.
Barchart · 04/12 18:49
Weekly Report: what happened at NUMIF last week (0401-0405)?
Weekly Report · 04/08 11:35
Weekly Report: what happened at NUMIF last week (0325-0329)?
Weekly Report · 04/01 11:32
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
PharmAla Biotech's with Numinus Wellness for a group therapy model with MDMA. Optimi Health's with Tel Aviv University for MDMA’s potential effects on addiction treatment. The two deals hit the wires on Tuesday. PharmAla will supply MDMA for a prospective clinical trial in Canada.
Benzinga · 03/26 19:35
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Utah's two largest healthcare systems may treat patients with psilocybin and MDMA as part of a pilot program. The pilot program will be open to providers at the University of Utah Health and Intermountain Health. The state's new law will take effect as early as May 1, 2024. The bill does not specify that hospitals can use the substances for treating conditions that have FDA approval.
Benzinga · 03/26 00:26
More
Webull provides a variety of real-time NUMIF stock news. You can receive the latest news about Numinus Wellness Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NUMIF
Numinus Wellness Inc. (Numinus) is a Canada-based health care company focused on creating an ecosystem of wellness solutions through access, research, training and therapies centered on psychedelic therapies. The Company, through its subsidiary Salvation Botanicals Ltd, has a Health Canada cannabis testing license and dealer’s license. The testing license allows the Company to test and analyze cannabis products from licensed producers, and the dealer’s license allows the Company to test, possess, buy and sell methylenedioxymethamphetamine (MDMA), psilocybin, psilocin, dimethyltryptamine (DMT) and mescaline. Numinus also operates a stand-alone center offering patients integrative health solutions.